Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
On Oct. 16, 2026, HALO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Halozyme Therapeutics, Inc. is a large-cap company with a market capitalization of $13.83B. It ranks number 9 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 96.34x is the highest of the 49 peers that report one. Its ROE of 288.1% is the highest of the 47 peers that report one.
For HALO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, HALO included.
Follow HALO free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
| Metric | HALO | Rank |
|---|---|---|
| Market Cap | $13.83B | 9/60 |
| P/E Ratio | 28.01x | 7/15 |
| P/B Ratio | 96.34x | 1/49 |
| EPS | $4.35 | – |
| Book Value/Share | $1.26 | – |
| Revenue/Share | $14.66 | – |
| FCF/Share | $7.10 | – |
| Metric | HALO | Rank |
|---|---|---|
| ROE | 288.1% | 1/47 |
| ROA | 16.1% | 7/50 |
| ROIC | 26.7% | 5/53 |
| Gross Margin | 82.4% | 7/24 |
| Operating Margin | 35.9% | 6/40 |
| Net Margin | 24.9% | 5/37 |
| EBT Margin | 35.1% | 6/42 |
| Tax Rate | 29.1% | – |
| Metric | HALO | Rank |
|---|---|---|
| Current Ratio | 2.71x | 47/59 |
| Quick Ratio | 2.31x | 19/28 |
| D/E Ratio | 16.96x | 1/53 |
| Financial Leverage | 17.96x | 1/52 |
| Working Capital | $589M | 22/59 |
| Metric | HALO | Rank |
|---|---|---|
| Operating Cash Flow | $819M | 8/57 |
| Free Cash Flow | $806M | 8/50 |
| Capital Spending | -$12M | 30/50 |
| OCF Growth YoY | 49.4% | 5/16 |
| FCF Growth YoY | 49.1% | 5/15 |
| FCF/Sales | 48.5% | 3/32 |
| CapEx/Sales | 0.7% | 31/32 |
| Metric | HALO | Rank |
|---|---|---|
| Asset Turnover | 0.65x | 9/36 |
| Receivables Turnover | 3.7x | 19/24 |
| Inventory Turnover | 2.1x | 14/23 |
| Fixed Assets Turnover | 33.4x | 5/37 |
| Days Sales Outstanding | 99 days | 6/24 |
| Days Inventory | 171 days | 10/23 |
| Payables Period | 29 days | 24/26 |
| Cash Conversion Cycle | 241 days | 2/18 |
| Metric | HALO | Rank |
|---|---|---|
| Total Revenue | $1.66B | 8/37 |
| Operating Income | $597M | 6/54 |
| Net Income | $414M | 7/50 |
| R&D Expense | $102M | 44/56 |
| SG&A Expense | $238M | 14/22 |
| Cost of Goods Sold | $292M | 11/26 |
| Metric | HALO | Rank |
|---|---|---|
| Shares Outstanding | 114M | – |
| Net Income Growth | -25.8% | 9/12 |
| EPS Growth | 7.7% | 8/14 |
| Total Current Assets | $933M | 36.2% of assets |
| Cash & Short-term Investments | $163M | 6.3% of assets |
| Accounts Receivable | $453M | 17.6% of assets |
| Inventory | $137M | 5.3% of assets |
| Total Liabilities | $2.43B | 94.4% of assets |
| Short-term Debt | $321M | 12.4% of assets |
Companies classified under the same SEC industry code as Halozyme Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▶ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▼ | $15.42B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▶ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▼ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $873M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $521M |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial ...
Good afternoon. My name is Joel, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's Second Quarter 2026 Financial and Operating Results ...
Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: ...
On Oct. 16, 2026, HALO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
For HALO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Halozyme Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, HALO included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.